Literature DB >> 11273715

The cardiac sodium channel: gating function and molecular pharmacology.

J R Balser1.   

Abstract

Cardiac sodium (Na) channels are dynamic molecules that undergo rapid structural changes in response to the changing electrical field in the myocardium. Inherited mutations in SCN5A, the gene encoding the cardiac Na channel, provoke life-threatening cardiac arrhythmias, often by modifying these voltage-dependent conformational changes. These disorders (i.e. the long QT syndrome and Brugada syndrome) may serve as valuable models for understanding the mechanistic linkages between Na channel dysfunction and cardiac arrhythmias in more common, acquired conditions such as cardiac ischemia. In addition, the balance between therapeutic and adverse effects from Na channel blockade by antiarrhythmic compounds may be shifted by subtle alterations in Na channel function. This review examines recent studies that tie key loci in the Na channel primary sequence to its dynamic function, while examining the emerging themes linking Na channel structure, function, and pharmacology to inherited and acquired disorders of cardiac excitability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273715     DOI: 10.1006/jmcc.2000.1346

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  44 in total

1.  In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.

Authors:  Martin Aguilar-Shardonofsky; Edward J Vigmond; Stanley Nattel; Philippe Comtois
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

2.  Quantitative modelling of interaction of propafenone with sodium channels in cardiac cells.

Authors:  M Pásek; J Simurda
Journal:  Med Biol Eng Comput       Date:  2004-03       Impact factor: 2.602

3.  Expression pattern of neuronal and skeletal muscle voltage-gated Na+ channels in the developing mouse heart.

Authors:  Volker Haufe; Juan A Camacho; Robert Dumaine; Bernd Günther; Christian Bollensdorff; Gisela Segond von Banchet; Klaus Benndorf; Thomas Zimmer
Journal:  J Physiol       Date:  2005-03-03       Impact factor: 5.182

4.  Computer simulation of wild-type and mutant human cardiac Na+ current.

Authors:  Stefania Vecchietti; Ilaria Rivolta; Stefano Severi; Carlo Napolitano; Silvia G Priori; Silvio Cavalcanti
Journal:  Med Biol Eng Comput       Date:  2006-03       Impact factor: 2.602

5.  Cellular mechanism and arrhythmogenic potential of T-wave alternans in the Brugada syndrome.

Authors:  Jeffrey M Fish; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2007-11-21

6.  The intracellular domain of the beta 2 subunit modulates the gating of cardiac Na v 1.5 channels.

Authors:  Thomas Zimmer; Klaus Benndorf
Journal:  Biophys J       Date:  2007-03-16       Impact factor: 4.033

Review 7.  Cardiac sodium channel mutations: why so many phenotypes?

Authors:  Man Liu; Kai-Chien Yang; Samuel C Dudley
Journal:  Nat Rev Cardiol       Date:  2014-06-24       Impact factor: 32.419

8.  The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.

Authors:  Naomasa Makita; Elijah Behr; Wataru Shimizu; Minoru Horie; Akihiko Sunami; Lia Crotti; Eric Schulze-Bahr; Shigetomo Fukuhara; Naoki Mochizuki; Takeru Makiyama; Hideki Itoh; Michael Christiansen; Pascal McKeown; Koji Miyamoto; Shiro Kamakura; Hiroyuki Tsutsui; Peter J Schwartz; Alfred L George; Dan M Roden
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

Review 9.  Brugada and long QT-3 syndromes: two phenotypes of the sodium channel disease.

Authors:  Ijaz A Khan; Chandra K Nair
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-07       Impact factor: 1.468

10.  Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome.

Authors:  Jeffrey M Fish; Daniel R Welchons; Young-Sup Kim; Suk-Ho Lee; Won-Kyung Ho; Charles Antzelevitch
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.